<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276093</url>
  </required_header>
  <id_info>
    <org_study_id>AF-10-023-ND-AB</org_study_id>
    <nct_id>NCT01276093</nct_id>
  </id_info>
  <brief_title>Pulmonary Vein Ablation Versus Amiodarone in the Elderly</brief_title>
  <acronym>PAVANE</acronym>
  <official_title>Pulmonary Vein Ablation Versus Amiodarone in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate that in patients of 70 years or older with
      symptomatic paroxysmal atrial fibrillation (AF) pulmonary vein isolation (PVI) using RF
      ablation therapy is superior to medical treatment with amiodarone to prevent recurrence of
      AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common arrhythmia. The prevalence of AF is highly age
      dependent as 70% of AF patients is between 65 and 85 years old. With increasing life
      expectancy, AF prevalence will increase 2,5 times during the next 50 years and constitute an
      even more important health concern. In younger patients Pulmonary vein ablation is an
      accepted procedure with superior efficacy compared to medical treatment. In this study the
      safety and efficacy of PVI in patients over 70 years old will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB recommendation; enrollment too slow
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of episodes of AF, atypical atrial flutter or left sided atrial tachycardia</measure>
    <time_frame>Until 1 year after post treatment blanking period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite end point of hospitalization, stroke, major bleeding and death</measure>
    <time_frame>Until last patient has been followed for 15 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary Vein Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiodarone medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI ablation</intervention_name>
    <description>Pulmonary Vein Ablation using RF.</description>
    <arm_group_label>PVI ablation</arm_group_label>
    <other_name>Pulmonary Vein Isolation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone tablets</description>
    <arm_group_label>Amiodarone medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 65 years at moment of screening, able to sign informed consent.

          -  Documented paroxysmal AF in association with complaints in the last year, with at
             least 2 episodes of complaints attributed to AF in the previous 2 months.

          -  Paroxysmal AF documented with at least one ECG with sinus rhythm not after
             cardioversion in the last year.

          -  No prior use of amiodarone in the last 6 months and no usage longer than 4 weeks in
             total.

        Exclusion Criteria:

          -  EF &lt; 35 % or description of &quot;poor left ventricular function&quot; on echocardiogram.
             Measurement should not be older than 6 months at moment of screening.

          -  Aortic, mitral, pulmonary or tricuspid valve regurgitation or stenosis, if graded
             severe (grade &gt;3)

          -  Acute illness: unstable angina, infectious disease.

          -  Primary structural or electrical heart disease: dilated cardiomyopathy, hypertrophic
             cardiomyopathy, Brugada syndrome, long QT syndrome.

          -  Reversible causes (thyroid dysfunction, uncontrolled hypertension, ischemia).

          -  Previous ablation.

          -  Contraindications for amiodarone; liver dysfunction (serum alanine aminotransferase
             &gt;2.5 times upper limit); thyroid dysfunction; chronic lung disease; baseline QTc &gt;460
             ms. sinus node dysfunction (pause more than 3 seconds in sinus rhythm); second or
             third degree AV-block.

          -  Contraindications for anti-coagulation: prior life threatening hemorrhage under use of
             Vitamin K antagonists.

          -  Any myocardial infarction or PCI in previous 6 months.

          -  CABG in previous 6 months.

          -  Renal dysfunction: creatinine clearance &lt;45 ml/min

          -  Severe co-morbidity. Life expectancy less than 1 year.

          -  Thrombus in left atrium

          -  Untreatable allergy to contrast media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Dekker, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elkerliek Hospital</name>
      <address>
        <city>Helmond</city>
        <state>Noord Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Center</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord Brabant</state>
        <zip>5504DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid Holland</state>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>PVI ablation</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

